Analyst Price Target is $3.50
▲ +253.54% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for vTv Therapeutics in the last 3 months. The average price target is $3.50, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 253.54% upside from the last price of $0.99.
Current Consensus is
The current consensus among 2 investment analysts is to buy stock in vTv Therapeutics.
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.